Corpus ID: 33151280

The differentiation inducing effect of bryostatin 5 on human myeloid blast cells is potentiated by vitamin D3.

  title={The differentiation inducing effect of bryostatin 5 on human myeloid blast cells is potentiated by vitamin D3.},
  author={Klaas G van der Hem and A. M. Dr{\"a}ger and Peter C. Huijgens and Chenghock Tol and W Devill{\'e} and Mart M. A. C. Langenhuijsen},
  volume={8 2},
Bryostatin 5 is a macrocyclic lactone which activates protein kinase C (PKC). PKC activation has been implicated in leukemic cell differentiation. We have examined the effect of PKC activation by bryostatin 5 on human acute myeloid cell differentiation in the presence and absence of vitamin D3. In vitro treatment of 20 patient samples of acute myeloid leukemias in a 4 days culture system with 10 nM bryostatin 5 induced strongly adherent macrophage-like cells in all cases. Bryostatin 5 induced a… Expand
Effects of bryostatin-5 and hematopoietic growth factors on acute myeloid leukemia cell differentiation, proliferation, and primary plating efficiency.
Findings indicate that the compound bryo-5 exerts an anti-proliferative effect on AML cells and counteracts growth factor induced leukemic proliferation. Expand
Bryostatin 1 (bryo1)-induced monocytic differentiation in THP-1 human leukemia cells is associated with enhanced c-fyn tyrosine kinase and M-CSF receptors.
Results show that enhanced expression and activation of fyn kinases are critical events associated with monocytic differentiation induced by bryo1 in THP-1 cells. Expand
Bryostatin-5 stimulates normal human hematopoiesis and inhibits proliferation of HL60 leukemic cells.
A possible role for bryostatin-5 in the treatment of acute myeloid leukemia is suggested after differential modulation of normal and leukemic myeloids clonogenicity by brystatin- 5. Expand
Heterogenous effects of bryostatin on human myeloid leukemia clonogenicity: dose and time scheduling dependency.
The effects of bryo on clonogenic leukemia cell growth are strongly dependent on scheduling and dose varying between and within individual AML samples, and caution against in vivo bryostatin-1 pulse therapy for treatment of AML. Expand
Differentiation of myeloid cells and 1,25-dihydroxyvitamin D3.
It is shown that transient exposure (24 h) of promyelocytes to 1,25(OH)2D3 causes Mo/Mphi differentiation and this strategy could be useful for examining the effects of 2D3 on the growth and differentiation of normal myeloblasts and myeloid progenitor cells. Expand
Phase IB study of 25-hydroxyvitamin D3 treatment to diminish suppressor cells in head and neck cancer patients
Results of these pilot studies showed that 25-hydroxyvitamin D(3) reduced the presence of immune suppressive CD34(+) cells and improved immune competence of HNSCC patients. Expand
Enhancement by other compounds of the anti-cancer activity of vitamin D(3) and its analogs.
There are extensive, but largely unexplored, opportunities to develop combinatorial, differentiation-based approaches to chemoprevention and chemotherapy of human cancer. Expand
Failure of tumor-reactive lymph node cells to kill tumor in the presence of immune-suppressive CD34+ cells can be overcome with vitamin D3 treatment to diminish CD34+ cell levels
Treatment of tumor bearers with vitamin D3 to eliminate CD34+ NS cells improves the anti-tumor effectiveness of adoptively transferred tumor-reactive lymph node cells. Expand
Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells
It is shown that CD34+ cells, whose frequency is increased in HNSCC patients, can be differentiated into cells that phenotypically and functionally resemble dendritic cells and that 1,25(OH)2D3 accentuates this differentiation. Expand
Bryostatin has proved to be a very potent antitumor-promoting agent, and a very promising anticancer drug, and it has provided curative levels of activity against a variety of murine experimental cancer systems. Expand